Compare UTHR & NTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTHR | NTRS |
|---|---|---|
| Founded | 1996 | 1889 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 24.3B |
| IPO Year | 1999 | N/A |
| Metric | UTHR | NTRS |
|---|---|---|
| Price | $504.73 | $138.23 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 14 |
| Target Price | ★ $495.08 | $127.77 |
| AVG Volume (30 Days) | 428.3K | ★ 960.4K |
| Earning Date | 10-29-2025 | 01-22-2026 |
| Dividend Yield | N/A | ★ 2.32% |
| EPS Growth | ★ 16.08 | 7.22 |
| EPS | ★ 26.38 | 8.58 |
| Revenue | $3,128,400,000.00 | ★ $7,932,900,000.00 |
| Revenue This Year | $13.64 | N/A |
| Revenue Next Year | $5.78 | $4.02 |
| P/E Ratio | $19.37 | ★ $16.06 |
| Revenue Growth | ★ 13.50 | 0.96 |
| 52 Week Low | $266.98 | $81.62 |
| 52 Week High | $513.93 | $140.75 |
| Indicator | UTHR | NTRS |
|---|---|---|
| Relative Strength Index (RSI) | 67.62 | 66.17 |
| Support Level | $483.52 | $137.44 |
| Resistance Level | $513.93 | $133.80 |
| Average True Range (ATR) | 11.03 | 2.53 |
| MACD | 1.04 | 0.53 |
| Stochastic Oscillator | 80.46 | 83.57 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of December 2024, Northern Trust had assets under custody or administration of $16.8 trillion and assets under management of $1.6 trillion.